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Abstract
Insulin synthesis in pancreatic beta cells is initiated as preproinsulin. Prevailing glucose 
concentrations, which oscillate pre- and post-prandially, exert major dynamic variation in 
preproinsulin biosynthesis. Accompanying upregulated translation of the insulin precursor include 
elements of the endoplasmic reticulum (ER) translocation apparatus linked to successful 
orientation of the signal peptide, translocation, and signal peptide cleavage of preproinsulin — all 
of which are necessary to initiate the pathway of proper proinsulin folding. Evolutionary pressures 
on the primary structure of proinsulin itself have preserved the efficiency of folding 
(“foldability”), and remarkably, these evolutionary pressures are distinct from those protecting the 
ultimate biological activity of insulin. Proinsulin foldability is manifest in the ER, in which the 
local environment is designed to assist in the overall load of proinsulin folding and to favor its 
disulfide bond formation (while limiting misfolding), all of which is closely tuned to ER stress 
response pathways that have complex (beneficial, as well as potentially damaging) effects on 
pancreatic beta cells. Proinsulin misfolding may occur as a consequence of exuberant proinsulin 
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biosynthetic load in the ER, proinsulin coding sequence mutations, or genetic predispositions that 
lead to an altered ER folding environment. Proinsulin misfolding is a phenotype that is very much 
linked to deficient insulin production and diabetes, as is seen in a variety of contexts: rodent 
models bearing proinsulin-misfolding mutants, human patients with Mutant INS-gene induced 
Diabetes of Youth, animal models and human patients bearing mutations in critical ER resident 
proteins, and, quite possibly, in more common variety type 2 diabetes.
Keywords
secretory protein biosynthetic pathway; polypeptide chain initiation; Sec61 translocon; disulfide-
linked protein complexes; unfolded protein response
1 | INTRODUCTION
The dynamics of insulin biosynthesis and secretion has been investigated in recent studies of 
normal human volunteers who received isotopic amino acid bolus labeling and 45 minutes 
later underwent a standard 75-g oral glucose tolerance test [1]. These studies indicate that 
~80% of the C-peptide released from beta cells over the ensuing 3.5 h is derived from ‘old’ 
(i.e., previously-made) hormone pools whereas only ~20% is newly-synthesized. As the 
storage pool of older insulin and C-peptide is vast, the small fractional contribution of new 
hormone nevertheless implies a ‘relative preference’ for the release of new insulin [2], 
particularly during the extended ‘second-phase’ of insulin secretion [1]. Significantly, these 
findings underscore the importance of insulin secretory pathway dynamics [3], as beta cell 
homeostasis requires the maintenance and repletion of the insulin granule storage pool. Such 
homeostasis is critically dependent upon the biosynthetic pathway [4–6] as well as granule 
turnover [7].
A pancreatic beta cell can readily synthesize 6000 preproinsulin molecules per second [8]. 
The process of folding new proinsulin includes injection of the nascent polypeptide into the 
lumen of the endoplasmic reticulum (ER) followed by signal peptide cleavage and formation 
of three proinsulin disulfide bonds that are evolutionarily conserved throughout the 
vertebrate insulin/IGF superfamily [9, 10]. Pancreatic beta cells folding this amount of 
proinsulin have significant ongoing ER stress response (e.g., spliced XBP1 protein) even in 
the absence of stimulation or addition of ER stressors [11]. After feeding, yet more 
proinsulin synthesis is required — and still more in insulin-resistant states such as pregnancy 
or obesity [12, 13].
The pathway of proinsulin folding has been analyzed in great detail by us and others, with a 
particular emphasis on how alterations in proinsulin disulfide bonding patterns in both 
rodent and human beta cells impact upon insulin production and secretion. Studies of Akita 
and Munich mouse models have shown that cysteine mutations in proinsulin interfere with 
proper disulfide bond formation. Such interference both aggravates ER stress and accounts 
for the onset of insulin deficient diabetes, culminating ultimately in beta cell loss [14, 15]. It 
is possible that even in the absence of such mutations, intracellular oxidative or reductive 
stress [16–18] could impair native disulfide pairing in proinsulin and in turn trigger the onset 
or progression of type 2 diabetes.
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In this article, we bring together and unify four perspectives that span the features of 
preproinsulin biosynthesis including the earliest steps that deliver the protein to and through 
the ER membrane; structural features preserved in the proinsulin molecule to facilitate its 
folding to the native state in order to achieve ultimate biological activity; pathways of 
regulation of the ER environment that are designed to sense proinsulin folding load and to 
optimize successful proinsulin biosynthesis; and factors that drive proinsulin misfolding in 
the ER in spite of the beta cell’s best efforts to limit this phenotype. These considerations 
lead us to the consequences of defects in any and all of the steps outlined herein: insulin 
production deficiency, beta cell ER stress, beta cell death, and diabetes.
2 | PREPROINSULIN BIOSYNTHESIS AND TRANSLOCATION ACROSS 
THE ER MEMBRANE
2.1 | ROUTES OF PREPROINSULIN ENTRY INTO THE ER
Newly synthesized preproinsulin is composed of the signal peptide followed by the entirety 
of proinsulin, including segments corresponding to the insulin B-chain, C-peptide, and 
insulin A-chain (Figure 1).
Preproinsulin biosynthesis is initiated in the cytosol. As a first step in insulin biosynthesis, 
newly synthesized preproinsulin must be guided by its signal peptide to the ER for 
translocation [19, 20]. In general, secretory preproteins can follow either co-translational 
and/or post-translational translocation routes into the ER. For preproinsulin, it had long been 
thought that only the signal recognition particle (SRP)-dependent co-translational 
mechanism was employed [21] in which translation is coupled to translocation into the ER 
[22–24]. Although this notion is compelling, emerging genetic and cell biological evidence 
indicates that preproinsulin translocation across the ER membrane is less efficient than 
previously thought [25–27]. Specifically, recent studies have shown that in isolated human 
islets and beta cell lines, during a 10-minute metabolic labeling period, about 5–15% of fully 
synthesized preproinsulin molecules are not translocated across the ER membrane. What’s 
more, this measurement underestimates the problem. Although preproinsulin translation 
itself is expected to require < 20 seconds [28], when the pulse-labeling period was shortened 
to 300 seconds (i.e., ~15-fold longer than the translational requirement), up to 40% of 
completed preproinsulin nascent chains had not yet been translocated into the ER, 
demonstrating the marked and unexpected inefficiency of its co-translational translocation 
[26, 27, 29]. That fully synthesized but untranslocated preproinsulin molecules are unstable 
in the cytosol highlights the importance of their rescue via the post-translational 
translocation route.
In 2012 it was reported that whereas inhibiting expression of a subunit of SRP or the SRP 
receptor could impair SRP-dependent co-translational translocation, preproinsulin 
translocation could nevertheless continue, seemingly unaffected [30]. By contrast, 
knockdown of Sec62 (which has been shown to facilitate the post-translational mechanism) 
impaired preproinsulin translocation, suggesting that this route contributes significantly to 
the overall efficiency of preproinsulin translocation (Figure 2).
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Indeed, an important fraction of translocation-dependent preproinsulin signal peptide 
cleavage was observed in beta cells to occur during the 10 minutes following completion of 
nascent chain biosynthesis [26], strongly supporting the notion that translocation of newly 
synthesized preproinsulin is co-translationally inefficient and is completed via a post-
translational mechanism.
The pathophysiological significance of defects in preproinsulin translocation and signal 
peptide cleavage is highlighted by recent discovery of six diabetogenic preproinsulin signal 
peptide mutations (Figure 1) [25, 27, 29]. As for most other secretory preproteins, the 
preproinsulin signal peptide is comprised of three regions, a positively charged “n-region”, a 
hydrophobic “h-region”, and a more polar “c-region”; illustrative studies of the 
consequences of an n-region mutation are shown in Figure 3.
Diabetogenic preproinsulin mutations have been found in all three regions of the signal 
peptide, but interestingly, mutants in these three regions are associated with distinct diabetes 
phenotypes, suggesting that the mutations may utilize distinct mechanisms and perturb 
different underlying steps in preproinsulin biosynthesis — each nevertheless leading to beta 
cell failure and diabetes [29, 31, 32].
2.2 | INTRACELLULAR MACHINERY INVOLVED IN POST-TRANSLATIONAL 
TRANSLOCATION OF PREPROINSULIN
Whereas the intracellular components involved in co-translational translocation of secretory 
preproteins are well-established, those involved in post-translational translocation are less 
well studied. The Sec61 translocon is a common route for both co- and post-translational 
translocation. However, unlike for co-translational translocation, preproteins undergoing 
post-translational translocation appear to have additional requirements in order to efficiently 
engage the Sec61 translocon. To date, analyses of secretory preproteins that undergo post-
translational translocation suggest that several cytosolic molecular chaperones, including 
Hsp70, TRC40, calmodulin, and Sec62/63 contribute to this pathway.
Hsp70 facilitates post-translational translocation, presumably by preventing aggregation of 
untranslocated preproteins — thereby maintaining translocation-competence [33–35]. The 
action(s) of Hsp70 might also account for the energy requirement of translocation. Proximity 
of calmodulin and TRC40 to signal sequences was demonstrated in crosslinking studies. 
Such binding is thought to maintain translocation-competence of preproteins and facilitate 
ER targeting and delivery. Inhibiting or downregulating either cytosolic protein was found to 
greatly impair post-translational translocation of preproteins [36, 37]. Additionally, two ER 
membrane proteins Sec62/63, are thought to be necessary for post-translational engagement 
with the Sec61 translocon [38, 39]. In the specific case of preproinsulin, Sec62 is the only 
component of the translocation machinery that has been experimentally confirmed to play a 
role in promoting post-translational translocation [30].
Another component that might contribute to the ER translocation of preproinsulin is the 
Translocon-Associated Protein complex (TRAP), which is also known as the Signal 
Sequence Receptor (SSR). A molecular neighbor of Sec61 [40, 41], TRAP was reported to 
facilitate initiation of protein translocation in a substrate-specific manner, especially for 
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preproteins with weak Sec61 interactions [42]. As preproinsulin is predisposed to inefficient 
translocation, it is possible that TRAP might enhance its efficiency, especially given that in a 
pancreatic beta cell line, mRNA encoding TRAP components are upregulated along with 
insulin mRNA in response to glucose stimulation [43]. Recently, a genetic polymorphism of 
TRAPα has been reported to be associated with type 2 diabetes, and with gestational 
diabetes [44, 45]. Additional studies will be needed to determine if the TRAP complex plays 
a role in insulin biosynthesis.
2.3 | INFORMATION INTRINSIC TO THE SEQUENCE OF PREPROINSULIN DETERMINES 
ITS ROUTE AND EFFICIENCY OF ER TRANSLOCATION
In addition to intracellular machinery, the biological properties of secretory preproteins are 
important factors in determining the translocation route chosen for entry into the ER. These 
intrinsic properties/signals include the length of the preprotein, the strength of the signal 
sequence, as well as structural information encoded in the proprotein beyond the signal 
peptide cleavage site [26, 30, 46, 47]. Among these factors, the length of the entire 
preprotein is one of the most important factors. Because SRP binding does not bring about 
complete translational arrest, smaller secretory proteins may easily be completed before SRP 
recognition or docking at the ER membrane, which leads to less efficient co-translational 
translocation: post-translational translocation is then enlisted “as a backup” mechanism. 
Indeed, a recent study compared the efficiency of translocation of hybrid proteins led by the 
preproinsulin signal sequence and followed by 70 – 300 amino acids. Co-translational 
translocation became gradually less efficient for preproteins containing fewer than 110 
residues (the length of authentic human preproinsulin). Indeed, for preproteins of ~70 
residues (thought to represent a minimal requirement for SRP binding), up to 70% of the 
molecules are not translocated into the ER upon completion of polypeptide synthesis [26]. 
This inefficiency tends to shift small secretory preproteins to the post-translational 
translocation route [48]. Given that many important cytokines and hormones (including 
insulin) are derived from small polypeptide precursors, the pathophysiological role of post-
translational translocation may be far more important than previously realized.
The strength of the signal sequence that is recognized and bound by SRP also contributes to 
the choice of translocation route. Among the three regions of the signal sequence, a strong 
and undisrupted hydrophobic h-region appears to be the most important element in 
determining the strength of SRP binding. A short h-region, or one disrupted by polar or 
charged residues, may thus be subject to inefficient SRP binding and ER translocation [47, 
49, 50]. The h-region of the human preproinsulin signal sequence contains at least 10 
hydrophobic residues that would in principle provide a relatively high score for SRP 
binding. Therefore, we attribute the low co-translational translocation efficiency of 
preproinsulin primarily to its short length (which allows for rapid completion of synthesis 
with escape from the co-translational process) rather than a structural inability to be 
recognized by SRP. Despite this predisposition to inefficient co-translational ER targeting, 
untranslocated preproinsulin molecules nonetheless find their way to the ER membrane [26, 
29, 31], presumably via the assistance of some of the machinery described in the preceding 
section.
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Upon delivery to the ER membrane, the preproinsulin signal peptide needs to be properly 
oriented within the Sec61 translocon, such that the n-terminus of the signal peptide faces the 
cytosolic side of the ER membrane. This orientation allows the cleavage site of the signal 
peptide to be exposed to signal peptidase on the luminal side of the ER membrane. Charged 
residues in the n-region, or the charge gradient flanking the h-region, helps to orient the 
signal peptide to align itself with the complementary charge gradient existing within the 
Sec61 channel [29, 51]. This model is consistent with the fact that about 70% of the 
eukaryotic secretory preproteins contain positively charged residues in their signal sequence 
n-regions [26, 52]. Preproinsulin in particular has a highly conserved positive charged 
residue at the 6th residue of its signal sequence. In the case of the preproinsulin-R6C mutant, 
elimination of the n-region positive charge results in inefficient preproinsulin translocation, 
predisposing to beta cell failure and diabetes in humans carrying the mutation [25, 29]. 
Remarkably, the same diabetogenic mutation does not cause a detectable translocation 
defect when the mutant signal peptide is part of larger secretory preproteins, indicating that 
the defect caused by loss of the n-region positive charge is manifest only in small secretory 
preproteins, i.e., those (like preproinsulin) that are more dependent upon post-translational 
translocation [26].
3 | PROINSULIN STRUCTURAL FEATURES THAT ARE A CONSEQUENCE 
OF EVOLUTIONARY PRESSURES TO PRESERVE FOLDABILITY
3.1 | CLINICAL MUTATIONS AS PROBES OF FOLDABILITY
Dominant mutations in the human insulin gene can lead to pancreatic beta cell dysfunction 
and diabetes due to toxic folding of a mutant proinsulin (the human MIDY syndrome; see 
section 5.1, below). Whereas the majority of mutations introduce or remove a cysteine as 
highlighted above (leading in either case to an unpaired thiol), non-cysteine-related 
mutations in principle identify key determinants of folding efficiency. Studies of such 
mutations suggest that the evolution of insulin has been constrained not only by the structure 
and function of the mature hormone, but also by the susceptibility of its single-chain 
precursor to impaired foldability. Broad conservation of these non-cysteine residues suggests 
that rules of proinsulin foldability are shared by a family of single-chain factors (such as 
mammalian insulin like growth factors; IGF-I and II) and in part within the superfamily of 
invertebrate insulin-like proteins [53–55].
3.2 | MECHANISM OF DISULFIDE PAIRING
Oxidative folding of globular proteins has often been probed by chemical trapping of 
disulfide intermediates [56]. Application of this approach to proinsulin and related 
polypeptides (such as foreshortened single-chain analogs [57] and IGFs [58]) demonstrated 
transient accumulation of one- and two-disulfide intermediates [59–61]. Successive steps 
yield partial folds via a sequence of free-energy landscapes (Figure 4A). The broad basin in 
such landscapes enables multiple trajectories to the native state (bottom of funnels) from an 
ensemble of unfolded and partially folded states. This perspective extends the classical 
disulfide-centered view of protein-folding intermediates [62] to encompass general 
biophysical principles of protein folding as an ensemble of atomic-level pathways [63–65].
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The landscapes “mature” from shallow to steep, enabling nascent proinsulin to fold stepwise 
on successive disulfide pairing. Preferred disulfide intermediates and their time course of 
accumulation, as defined by chemical trapping, thus corresponds to multiple folding 
trajectories on a progression of landscapes. Each landscape regulates the dynamics of 
accessible polypeptide conformations in the presence of a specific subset of disulfide 
bridges. MIDY mutations may in principle skew the shape of a particular landscape and/or 
block the transition from one to the next.
Refolding studies of native proinsulin (distinct from analogous studies of model systems and 
homologs) have been limited by aggregation, which has restricted such studies to be 
conducted at pH conditions above 9; this restriction has, at least in part, confounded 
interpretation in relation to mechanisms of folding and misfolding pertinent to conditions in 
the ER [67]. The disulfide pathways of mini-proinsulin and IGF-I are by contrast well 
characterized near neutral pH as investigated by several laboratories [59–61, 68–71]. A 
consensus pathway is shown in Figure 4B [68, 72–80]. In this scheme a pivotal role is 
played by A20-B19, the favored initial cystine. In the three-dimensional structure of native 
insulin, this disulfide bridge packs within a cluster of conserved side chains in the 
hydrophobic core, connecting the C-terminal α-helix of the A chain to the central α-helix of 
the B chain [81–83]. Because cystine A20-B19 is the only one-disulfide species to 
accumulate in the refolding of model- or homologous polypeptides [60, 61, 71], its pairing is 
envisioned to stabilize a specific folding nucleus [73, 80, 84].
3.3 | STRUCTURAL MODELS OF FOLDING INTERMEDIATES
The above findings motivated construction of analogs (of insulin, mini-proinsulin, and IGF-
I) containing pairwise substitution of the other cysteines by Ala or Ser [68, 70, 72, 74–80]. 
Such analogs exhibit attenuated α-helix content as probed by circular dichroism (CD). 
Nucleation of native-like structure was nonetheless observed by isotope-directed 1H-13C 
NMR spectroscopy in a disulfide-linked two-chain fragment of IGF-I containing cystine 
A20-B19: at low temperature the disulfide bridge native tethers α-helices within a native-
like cluster of nonpolar side chains [80]. Mutations within this A20-B19-associated 
subdomain impair disulfide pairing in insulin chain combination and the biosynthesis of 
single-chain precursors in Saccharomyces cerevisciae [75, 84–87].
Remarkably, 1H-NMR spectra of the above equilibrium models were found to exhibit a 
progressive chemical-shift dispersion with successive disulfide pairing, reflecting stepwise 
stabilization of structure in accordance with the successive landscape paradigm [68, 73]. 
After A20-B19 pairing, folding can proceed through several alternative channels. Oxidative 
refolding of mini-proinsulin, for example, exhibits subsequent rapid formation of cystine 
A7-B7 (lower pathway in Figure 4B) or slow pairing of A6-A11 (upper pathway). Although 
it is not intuitive why pairing of cysteines distant in the sequence (A7 and B7) is favored 
relative to pairing of nearby cysteines (A6 and A11), spectroscopic studies revealed that 
pairwise serine substitution of cystine A7-B7 destabilizes the structure of insulin more 
markedly than analogous removal of A6-A11 [84]. These findings suggest that nascent 
structure in the one-disulfide [A20-B19] intermediate either more effectively aligns CysA7 
and CysB7 or more significantly impairs pairing of CysA6 and CysA11. Either on-pathway 
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two-disulfide intermediate may interconvert with non-native disulfide isomers as off-
pathway kinetic traps (central panel of Figure 4B).
3.4 | NON-NATIVE DISULFIDE PAIRING
The hazard to pancreatic beta cells posed by competing traps in the folding of proinsulin in 
the ER is considered in subsequent sections. The susceptibility of nascent proinsulin to 
forming non-native states is suggested by the aberrant refolding of a homologous 
polypeptide (IGF-I), which in vitro forms native and non-native disulfide isomers as 
alternative ground states (native IGF-I and IGF-swap) [59, 60]. Containing respective 
pairings [A20-B19, A7-B7, A6-A11] (native) and [A20-B19, A6-B7, A7-A11] (swap), the 
isomers exhibit similar core structures near the shared A20-B19 disulfide bridge [60, 88]. In 
a “mini-IGF” model, the relative stabilities of these disulfide isomers is influenced by the N-
terminal segment of the B domain [89, 90]. In human proinsulin an homologous non-native 
isomer and yet another (with pairings [A20-B19, A11-B7, A6-A7]) forms in the presence of 
a chemical denaturant [83]. Whereas the stability of IGF-swap is similar to that of native 
IGF-I, the accessible non-native isomers of insulin and proinsulin are molten globules of 
marginal stability [82].
Evidence for the pathological relevance of non-native disulfide isomers of proinsulin and 
related polypeptides has been obtained in eukaryotic cell culture [91–95]. Non-native 
isomers of human proinsulin are readily resolved in an SDS-polyacrylamide gel based 
system (described further in Section 5, below). Amino acid substitutions in human 
proinsulin can enhance the fraction of mispairing in the ER [92, 93]. Because propensity to 
misfold in this assay does not correlate with effects of the substitutions on thermodynamic 
stability in vitro, its mechanism is not well understood.
3.5 | DETERMINANTS OF NATIVE DISULFIDE PAIRING
Non-cysteine-related MIDY mutations are broadly distributed in the B chain of insulin. “Hot 
spots” occur in the N-terminal segment (residues B1-B8), central α-helix (B9-B19), and 
adjoining beta-turn (B20-B23) together with its aromatic anchor (PheB24). An overview of 
key positions in these elements in provided in Figure 5. Each mutation site provides insight 
into a structural determinant of native disulfide pairing.
We will discuss specific examples in the direction C →N as the C-terminal element of the B 
chain undergoes a change in conformation to serve a dual role in self-assembly and receptor 
binding [96].
The C-terminal segment of insulin (residues B24-B30) has attracted intensive investigation 
as it plays a central role in both homodimerization and receptor binding. Structure-function 
relationships pertinent to dimerization have been extensively investigated since elucidation 
of the crystal structure of insulin by Hodgkin and colleagues in 1969 [97]. An overview of 
this process is shown in Figure 6A.
The recent co-crystal structure of insulin bound to a fragment of the insulin-receptor (IR) 
ectodomain has provided evidence for induced fit within the C-terminal segment B-chain 
[100]. As predicted based on studies of “anomalous” insulin analogs [101–103], detachment 
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of the C-terminal beta-strand (B24-B27) enables its docking in a groove between the N-
terminal L1 beta-helical domain of the IR α-subunit and its dimer-related C-terminal 
element, an α-helix denoted αCT. Pre-detachment of the B-chain beta-strand by a chiral 
perturbation (e.g., substitution by PheB24 by D-Ala) was observed to enhance receptor 
binding at the expense of increased susceptibility to fibrillation [103]. Induced fit of the B 
chain may thus represent an evolutionary response to the danger of proteotoxicity: self-
assembly of the closed state protects the hormone from fibrillation.
PheB24 (shown in red in Figure 6A) is invariant among vertebrate insulins and IGFs. Its 
aromatic ring anchors the native B-chain beta-strand against the α-helical core of the insulin 
monomer. Such anchoring stabilizes the hydrophobic core and contributes to dimerization 
(and thus zinc hexamer assembly) [99]. Repositioning of PheB24 enables induced fit on 
receptor binding [103] and engages with the receptor [104, 105]. Recent advances in the 
crystallographic analysis of the IR ectodomain as an inverted-V dimer (Figure 6B) has led to 
the identification of the primary hormone-binding elements, L1 and αCT [106, 107]. 
Repositioning of aCT on the surface of L1 requires repositioning of PheB24 and 
displacement of residues B24-B30 as highlighted by superposition of the classical T state 
into a model complex (Figure 6C).
Whereas substitution of PheB24 by Cys leads to a prototypical MIDY phenotype 
(presumably due to an odd number of cysteines, as in the Akita allele) [108], substitution by 
Ser was identified more than 30 years ago (by a team of investigators at the University of 
Chicago including the late D.F. Steiner, memorialized at this symposium) as a classical 
insulinopathy [111]. Associated with a native-like structure in NMR studies [112], this 
mutation led onset of diabetes in the proband’s third decade of life rather than in infancy. 
Penetrance was variable in the pedigree.
Unlike classical insulinopathies PheB25→Leu (insulin Chicago) and ValA3→Leu (insulin 
Wakayama), which markedly impair receptor binding [113, 114], SerB24-insulin retains 
substantial (although reduced) biological activity [115]. Studies of the proband indicated that 
the mutant and wild-type proinsulins were each processed and secreted into the bloodstream 
[115]. Biochemical and cell biological studies have nonetheless uncovered defects in the 
variant precursor’s efficiency of folding, leading to aberrant induction of ER stress. 
Significantly, the level of ER stress was observed to be less than that associated with 
neonatal-onset MIDY mutations [115–117].
We speculate that heterozygous inheritance of the SerB24 mutation contributes to a lifelong 
burden of ER stress in pancreatic beta cells; whether this burden leads to adult-onset 
diabetes presumably depends on genetic background, i.e., co-inheritance of other genetic 
variants that mitigate or accentuate ER stress in beta cells.
B20-B22 β-Turn.—The super-secondary structure of the insulin B chain requires a β-turn 
between its central α-helix (residues B9-B19) and C-terminal β-strand. This turn contains 
conserved glycines at B20 and B23, which each exhibit a positive ϕ dihedral angle 
(ordinarily forbidden to L-amino acids). Whereas Ala substitutions impair the expression of 
mini-proinsulin in S. cerevisciae and impede chain combination, efficient disulfide pairing 
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can be rescued by D-amino acid substitutions [87]. A MODY mutation has been found at 
B23 and is expected to perturb pairing of cystine A20-B19. The structural mechanism by 
which a mutation at B22 (Arg→Gln; see above) causes a milder phenotype (analogous to 
Maturity-Onset Diabetes of the Young; MODY) is not apparent [117, 118].
Central α-helix.—Nascent folding of the B-chain α-helix was found in equilibrium 
models of the key [A20-B19] folding intermediate [68, 80] and subsequent two-disulfide 
intermediates [75, 78, 79, 84]. In these models LeuB11 and LeuB15 each contributed to 
clustering of nonpolar residues. MIDY mutations at these sites presumably block initial 
disulfide pairing and, should native disulfide pairing be achieved, perturb native structure 
and assembly. Indeed, Ala substitutions at B11 and B15 (although helicogenic in model 
peptides) impair the expression and secretion of mini-proinsulin in S. cerevisciae [86]. 
Whereas MIDY mutation LeuB15→Pro would be expected to destabilize the entire central 
α-helix, even subtle substitutions in this helix have been found to impair insulin chain 
combination. A prominent example is provided by simple interchange of LeuB11 and ValB12, 
predicted to perturb tertiary structure without net change in intrinsic helical potential [119]. 
It is not clear why substitution of TyrB16 by His, predicted to project at the surface of this α-
helix [120], may impair folding.
N-terminal segment.—In both the solution structure of insulin [72, 102, 121] and its 
crystallographic T-state [99, 122], residues B1-B6 are extended (asterisk in Figure 5) 
whereas B7-B10 comprise a β-turn adjoining the central α-helix. N-terminal residues 
contribute to the specification of the A7-B7 disulfide bridge in vitro [89, 90] and to the 
overall efficiency of proinsulin folding in cell lines [98]. In the classical TR transition 
among zinc insulin hexamers [123], this segment reorganizes as an α-helix to extend the 
central α-helix of the B chain. Although pertinent to insulin pharmacology [124], the 
physiological significance of the R state (if any) is not well understood.
Sites of MIDY mutation (HisB5 and GlyB8; broadly conserved among vertebrate insulins) 
have been well characterized [94, 125–127]. (i) In the native state HisB5 packs within an 
inter-chain crevice, making one or more hydrogen bonds to carbonyl oxygens in the A chain. 
Diverse substitutions impair chain combination [94]; ArgB5 (which is observed in some non-
mammalian insulins) is by contrast well tolerated, presumably through formation of 
analogous inter-chain hydrogen bonds as visualized in its crystal structure [127]. In 
mammalian cell culture substitution of HisB5 by Asp blocks the folding and secretion of 
human proinsulin [94]. (ii) In the T state GlyB8 exhibits a positive ϕ dihedral angle (like 
GlyB20 and GlyB23 above). Whereas only ArgB8 and SerB8 have been found to date in 
patients, any L-amino-acid substitution impairs chain combination; yield is by contrast 
rescued by D-substitutions [125]. Such stereospecificity suggests that the sign of the B8 ϕ 
angle contributes to the alignment or misalignment of neighboring CysB7 for disulfide 
pairing.
SerB8-insulin retains substantial biological activity [125]. The solution structure of SerB8 
insulin as an engineered monomer retains native-like features yet reduced thermodynamic 
stability [94, 126]. Whereas decreased native-state stability can in principle contribute to 
misfolding, it is likely that a chiral main-chain perturbation at B8 may also impose a kinetic 
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block to disulfide pairing, such as via decreased stabilities of populated folding 
intermediates. Evidence for such kinetic blocks has been provided by cellular studies in 
which this and related mutations lead to formation of non-native disulfide isomers [94, 126]. 
Alternatively, it is possible that these residues contribute to interactions of nascent proinsulin 
with ER chaperones and the oxidative machinery of disulfide pairing [128]. Interestingly, the 
substantial biological activities of SerB8-insulin and other “non-foldable” analogs [94, 98, 
126] indicates that residues required for efficient folding may be dispensable for the 
biological activity of the native state, once reached [129, 130].
3.6 | THE INSULIN A CHAIN
The relative paucity of non-cysteine-related mutations in the A domain of proinsulin among 
MIDY patients investigated to date may seem surprising, yet this may merely reflect an 
incomplete sampling of patients. Certainly, substitutions at the conserved sites LeuA16 and 
TyrA19 do impair the efficiency of chain combination [86, 131, 132]. It is also possible that 
conserved non-cysteine residues in the A domain (IleA2, AsnA18, TyrA19, AsnA21) play a 
less critical role in disulfide pairing than do analogous internal residues in the B domain. 
Both explanations may have partial validity. On the one hand, studies of the mechanism of 
chain combination have shown that the N-terminal A-chain α-helix (residues A1-A8) is not 
required for disulfide pairing [81]. Such dispensability is in accord with a putative structural 
pathway in which segmental folding of this α-helix is a late event (Figure 4B). On the other 
hand, the efficiency of chain combination is exquisitely sensitive to substitutions of core 
residue in the C-terminal A-chain α-helix (LeuA16 and TyrA19; purple spheres in Figure 5) 
[131, 133], and in fact mutation of LeuA16 has recently been recognized as a cause of human 
MIDY [134]. Thus we would expect that continued genetic screening of MIDY patients may 
well uncover additional non-cysteine-related A-chain mutations.
4 | DYNAMIC REGULATION OF THE ER ENVIRONMENT IN REPSONSE TO 
SUCCESSFUL AND UNSUCCESSFUL PROINSULIN BIOSYNTHESIS
4.1 | UNFOLDED PROTEIN RESPONSE
It is important to understand how an increase in proinsulin folding load can cause ER stress, 
and conversely how ER stress conditions affect proinsulin folding. The most ancient, 
conserved ER stress response (unfolded protein response, or UPR) is signaled through 
activation of the Inositol-Requiring Enzyme 1 (IRE1), a protein kinase and endoribonuclease 
(described below). Two more recent evolutionary developments in ER stress signaling 
include the Protein kinase-like Endoplasmic Reticulum Kinase (PERK) and the transcription 
factor ATF6 [135–137].
It is generally believed that both active and inactive subpopulations of the three ER stress 
sensors co-exist in normal cells, with the proportion of the active subfractions linked to 
cellular physiology and secretory pathway activity. The inactive subpopulations of ER stress 
sensor proteins are thought to be engaged in interactions with the ER protein chaperone BiP. 
An increased load of misfolded proteins in the ER effectively recruits BiP, thereby 
promoting a shift in BiP distribution away from PERK, IRE1 and ATF6 [138, 139], which is 
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strongly correlated with an increase in the size of the active subpopulations for these stress 
sensor proteins (Figure 7).
Individually, the PERK-eIF2α phosphorylation pathway serves as a translational brake that 
can help to alleviate ER protein load upon ER stress. There are multiple lines of evidence 
implicating inadequacy of PERK signaling as a possible trigger for proinsulin misfolding. 
Perk gene deletion in the mouse recapitulates many of the defects of the human Wolcott-
Rallison syndrome including diabetes associated with degeneration of β-cell mass after birth 
[140, 141]. In these studies, ER distention, a morphological indicator suggesting ER stress, 
was observed by electron microscopy in pancreatic beta cells from Perk null mice. 
Normoglycemia can still be maintained with a 95% deletion of PERK within the adult beta 
cell population in mice that have not been challenged with high fat diet or other causes of 
insulin resistance [141]. Nevertheless in the setting of insufficient PERK activity, the rate of 
glucose-stimulated proinsulin synthesis is enhanced (although such a conclusion has been 
recently challenged [142]), which is most consistent with the notion that loss of PERK 
kinase activity results in a loss of homeostatic maintenance of newly-synthesized proinsulin.
Activated PERK phosphorylates the α-subunit of the eukaryotic translation initiation factor 
2 (eIF2α) at Ser residue S51, leading to rapid, reversible inhibition of mRNA translational 
initiation [143]. The heterotrimic GTPase eIF2 is required to bring initiator methionyl 
tRNAMet to the 40S ribosome for AUG initiation codon recognition [144]. Phosphorylation 
of eIF2α to generate eIF2α-P inhibits the GDP/GTP exchange reaction of the eIF2B 
complex, thereby preventing eIF2 guanine nucleotide recycling which accompanies the 
initial step of protein synthesis [143, 145]. The S51A phosphorylation mutant in the eIF2α 
locus was introduced into mice that, globally, cannot phosphorylate the mutant eIF2α by any 
of the four known eIF2α kinases [145]. Homozygous mutant mice die perinatally due to 
hypoglycemia and defective hepatic gluconeogenesis. However, heterozygous eIF2α-S51A 
mice survive without a significant phenotype. Importantly, when fed a HFD that triggers 
insulin resistance, these mice develop beta cell failure and overt diabetes [146]. In addition, 
since the eIF2α-S51A mutation in beta cells recapitulates all the effects of PERK deletion in 
mice and humans [147], the findings support the notion that PERK acts through eIF2α-P, 
one important consequence of which is attenuation of proinsulin (and other protein) 
accumulation in the ER, thereby limiting further ER stress. In the setting of unusually 
increased levels of proinsulin misfolding, CHOP protein (controlled primarily via the PERK 
branch of the UPR pathway) can contribute to beta cell death associated with unsuppressed 
protein synthesis and increased generation of intracellular reactive oxygen species ROS 
[144, 148]. Importantly, deletion of the ER stress-induced proapoptotic gene Chop delayed 
onset of hyperglycemia in the Akita mouse [149] and suppressed β-cell failure in response to 
insulin resistance in diet-induced obese mice and db/db mice db/db mice [150]. To 
summarize, for the PERK branch of the UPR, although free fatty acids, cytokines and high 
glucose are proposed to cause β-cell failure, analysis of mice with eIF2α-S51A mutation or 
Perk deletion [140, 141] supports the notion that dysregulated proinsulin handling in the ER 
is sufficient to initiate β-cell failure.
The two other branches of the ER stress response, namely, the IRE1α and ATF6α pathways, 
also impact proinsulin folding by controlling ER proteostasis [137, 151, 152]. Although 
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there are α- and β-alleles of both IRE1 and ATF6 in the mammalian genome, IRE1α is 
ubiquitously expressed (whereas IRE1β is more narrowly expressed, particularly in 
intestinal epithelial cells) and ATF6α contributes more broadly to UPR signaling (whereas 
ATF6β has a far more limited activity in beta cells [153]).
IRE1α auto-phosphorylation activates a cytosolically-oriented domain of the protein 
encoding an endoribonuclease that initiates non-conventional splicing of Xbp1 mRNA 
[151], removing a 26-base intron that leads to a shift in the translational open reading frame 
to produce a highly active bZiP transcription factor, XBP1s. XBP1s activates genes encoding 
ER protein translocation, ER chaperones, lipid biosynthetic enzymes and ERAD functions 
[154, 155], all of which are thought to be needed for glucose-stimulated insulin secretion 
and cell adaptation and survival in response to physiological demand [156].
Activation of the ATF6α pathways is highly analogous to the SREBP activation pathway in 
that upon release from BiP, unsequestered ATF6 traffics to the Golgi complex where it gets 
cleaved by S1P and S2P proteases to produce a 50 kDa cytosolic fragment that translocates 
to the nucleus to serve as a potent transcriptional activator on genes that have 
complementary or overlapping functions to those activated by XBP1s [152]. Studies 
implicate an important role of ATF6 in β-cell function and survival [157, 158]. Collectively, 
the XBP1s and ATF6 pathways serve a central function to maintain a productive ER protein 
folding environment, to increase ER-associated degradation (ERAD) to degrade misfolded 
proinsulin [151, 152], and to help maintain the islet population of mature differentiated beta 
cells [159, 160]. Indeed, cells deficient for Ire1α, Xbp1 or Atf6α are defective in ERAD 
[161–163]. The importance of ERAD in normal cellular physiology has recently been 
reviewed elsewhere [164].
4.2 | THE PROTEIN DISULFIDE ISOMERASE (PDI) FAMILY OF ER OXIDOREDUCTASES, 
AND ERO1 AS AN UPSTREAM ER OXIDASE
The ER maintains a highly oxidizing intraluminal environment [17], which is considered 
crucial for proper proinsulin folding [165]. The protein disulfide isomerase (PDI) family of 
ER-resident proteins are strongly implicated in the oxidative folding of secretory proteins 
including proinsulin [166, 167]. Pancreatic islets are enriched in mRNA for PDIA1 [168], 
along with other abundant PDI-like oxidoreductase family members, such as ERp72 
(PDIA4), P5 (PDIA6), ERp57 (PDIA3), PDIp (PDIA2), and ERp44, and may be further 
enriched in islets experiencing ER stress [169–172]. Although PDIA1 is important for 
correct proinsulin oxidative folding in vitro [173, 174], it is currently unknown if PDI plays 
any essential role for proinsulin oxidation in vivo [175], although it might play additional 
roles in the fate of proinsulin in pancreatic beta cells [176].
To the extent that PDI proteins oxidize proinsulin or other substrates, their own catalytic 
cysteine thiols need to become re-oxidized in order to promote further cycles of substrate 
oxidation. In pancreatic beta cells, there is abundant expression of ERO1α, which is 
ubiquitous to all cells, and there is additional selective high expression of ERO1β [177], 
which can also serve as a major oxidase for beta cell ER oxidoreductases [178, 179]. ERO1β 
regulates susceptibility to ER stress and can be induced by proinsulin flux [180]. In vivo, 
Ero1β deficiency produces a phenotype of increased proinsulin entrapment in the ER, which 
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is associated with lower beta cell insulin content and reduced insulin secretion [178]. 
Nevertheless, not all PDI family members require ERO1 to catalyze their re-oxidation 
(although such re-oxidation is thought necessary to allow PDI-mediated substrate oxidation 
to continue), suggesting the possibility of alternative oxidative recycling pathways for PDI 
family members [181, 182].
4.3 | ER REDOX BALANCE AND THE POTENTIAL THERAPEUTIC UTILITY OF 
ANTIOXIDANTS
A substantial quantity of hydrogen peroxide (H2O2) is formed as a by-product of the ERO1-
catalyzed disulfide-formation pathway [183], although it is not clear that these particular 
ROS forms meaningfully escape the ER to attack other cellular compartments [184], and to 
the extent that they do, this might actually be beneficial for insulin gene expression [185]. 
Chemically, H2O2 in the ER forms at least in part via the action of ERO1 proteins, which 
utilize thiol-mediated electron transfer from members of the PDI family of oxidoreductases 
to molecular oxygen (Figure 8, and see below).
Alternatively, ROS may also be generated as a consequence of a futile cycle of oxidizing and 
reducing glutathione (GS-SG and GSH, respectively [181]). As a consequence, pancreatic 
beta cells, bearing the large load of proinsulin that must assemble three disulfide bonds per 
molecule, may be more susceptible to ER protein misfolding in response to overactivity of 
various oxidative enzymes [186]. In theory, pancreatic beta cells could utilize the activity of 
peroxiredoxin-4 (PRDX4) to consume H2O2 in the ER in order to make additional 
proinsulin disulfide bonds and resist ER stress [187]; however, evidence to date has 
suggested a limited expression of PRDX4 in rodent islet beta cells [188], although it 
becomes induced in islets of rodents upon high fat diet [189].
Interestingly, under certain circumstances, antioxidant treatment can effectively reduce ER 
stress and subsequent cell death [190]. This effect may be partially attributed to improved 
ER protein folding efficiency in cells with reduced oxidative stress. Feeding with a diet 
supplemented with the chemical antioxidant butylated hydroxyanisole (BHA), or deletion of 
the ER stress-induced proapoptotic gene Chop, significantly improved glucose homeostasis 
and restored beta cell function in mice bearing beta cell deletion of p58ipk (discussed below), 
the ER co-chaperone for BiP which is linked to proinsulin misfolding [148]. Intriguingly, 
antioxidants (i.e. BHA) can improve proinsulin folding and reduce apoptosis under 
conditions of ER stress [148], These data provide support that in the face of ER stress, 
restoration of cellular redox balance with appropriate antioxidants can improve beta cell 
viability and function, and that a critical aspect of the improved function is an improvement 
in proinsulin folding in the ER lumen [148].
Collectively, these data underscore that appropriate levels of ROS generation and scavenging 
are necessary for proper proinsulin folding, while excessive protein synthesis and unfolded 
ER protein accumulation can cause an imbalance of ROS and uncontrolled oxidative stress, 
predisposing to beta cell death [148, 150, 191].
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4.4 | ER QUALITY CONTROL OF PROINSULIN ANTEROGRADE EXPORT
BiP is the most abundant ER protein chaperone and it functions by binding to hydrophobic 
patches [192, 193] in unfolded/misfolded proteins [194, 195]. Therefore, to a first 
approximation, the extent of proinsulin misfolding can be monitored by the extent of its 
interaction with BiP [146]. Importantly, such association with BiP [196, 197] (as well as 
other ER-resident peptide-binding proteins such as GRP94 [198]) participates critically in 
the mechanism of retention of unfolded proteins within the ER lumen (ER quality control).
Importantly, in high fat diet (HFD) fed mice that do not bear any INS gene mutation, 
heterozygosity for eIF2α-S51A, which results in exuberant proinsulin biosynthesis, results 
in a dramatic increase of proinsulin interaction with BiP [146], underscoring a critical 
interaction between gene (heterozygous eIF2α-S51A) and environment (HFD) in 
predisposition to beta cell failure. On the other hand, p58IPK is a molecular co-chaperone 
that is proposed to stimulate the ATP hydrolysis activity of BiP, which is necessary for the 
cyclical binding/release of BiP to its client proteins [199]. Indeed, p58IPK/DNAJc3 deleted 
mice develop oxidative stress in beta cells, with loss of beta cell mass, leading to diabetes at 
about 6 weeks of age [200, 201]. Although there is still debate on the ER localization of 
P58IPK [201, 202], biochemical study supports its direct involvement in assisting Akita 
mutant proinsulin folding, together with PDIA6 [167]. Interestingly, p58IPK mutation in 
humans is also associated with diabetic complications and multi-systemic neurodegeneration 
[203].
4.5 | ER CALCIUM BALANCE
Last but not least, proinsulin folding in the ER is affected by ER calcium homeostasis. The 
ER is a dominant storage organelle for calcium in metazoans [204]. The most abundant ER 
resident proteins, including GRP94, BiP/GRP78, PDI, calreticulin, and others, are 
influenced by calcium binding, and these chaperones may in turn affect proinsulin folding. 
In addition, pancreatic islets exhibit glucose-dependent cytosolic calcium oscillations in 
electrical activity, which are coupled with ER calcium changes [205, 206].
Calcium accumulation in the ER lumen is maintained by the Sarcoplasmic/Endoplasmic 
Reticulum Calcium ATPase (SERCA) family of calcium pumps. The SERCAs are encoded 
by three genes (Serca1, Serca2, and Serca3), and their variety and activity are further 
diversified by the existence of splice variants and responses to ER stress [207]. SERCA2b 
and SERCA3 are the most abundant isoforms expressed in pancreatic beta cells [208, 209] 
and are largely responsible for maintaining the ER free calcium concentration in the 
physiological range of up to ~500 μM [210]. SERCA pumps and store-operated calcium 
channels restore ER luminal calcium upon the rapid release of ER calcium that occurs when 
beta cells are acutely stimulated. Although impaired SERCA function has been implicated in 
T2D models [211], mice with Serca3 deletion have normal basal glucose levels and glucose-
stimulated insulin secretion. Indeed studies of Serca3 deleted murine islets model [208, 209] 
have led to several insightful conclusions: 1) Basal cytosolic calcium is mainly set by 
mechanisms other than SERCA pumps; 2) The initial phase of increased cytosolic calcium 
can be taken up by the ER in a SERCA-dependent manner; 3) During the later phase of 
cytosolic calcium oscillations, the ER pool modulates the frequency and amplitude of these 
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oscillations. Interestingly, altered cytosolic calcium oscillation from Serca3 deleted islets is 
associated with increased insulin secretion in response to glucose stimulation [208, 209]. 
Thus the ER calcium pool may influence insulin secretory release in response to nutrients. 
Finally, although theoretically possible [206], it is unknown if ER Ca2+ concentrations may 
fluctuate under physiological and pathophysiological conditions to a level that could affect 
proinsulin folding under the influence of calcium-sensitive chaperones and oxidoreductases 
[204, 212].
Inositol 1,4,5-tri-Phosphate Receptors (IP3Rs) are a main source of acute calcium release 
from the ER. IP3Rs are encoded by three genes (Itpr1, Itpr2 and Itpr3), with splicing variants 
that display a range of IP3 binding affinities, with activation that affects cytosolic calcium 
concentration [213]. The IP3Rs form tetrameric channels that are distributed throughout the 
ER in clusters, and these clusters are considered calcium release “hot-spots” [204, 214]. 
Another class of calcium release channels is composed of the ryanodine receptors (RyR), 
which are encoded by three genes (Ryr1, Ryr2, and Ryr3). RyRs are not highly expressed in 
pancreatic islets, and may contribute little to the ER Ca release in beta cells.
Although calcium homeostasis in the ER of pancreatic beta cells is far more complex topic 
than what is described above, a basic understanding is that: 1) Free calcium concentration in 
the ER lumen regulates ER chaperones and oxidoreductases to facilitate proinsulin folding, 
and 2) The free calcium in the ER lumen is also expected to have an effect on cytosolic 
calcium bursts that fine-tune insulin granule exocytosis in response to nutrients such as 
glucose and amino acids.
5 | PROINSULIN IN DIABETOGENIC CONDITIONS: MISFOLDED STATES IN 
THE ER
In spite of the fact that proinsulin biosynthesis is tightly coordinated with metabolic demand 
via physiological ER stress response (especially the activities of IRE1α/XBP1 to regulate 
expression of much of the ER machinery necessary for successful proinsulin and insulin 
biosynthesis [11, 156, 215]) — it is increasingly recognized that proinsulin is highly 
susceptible to misfolding [9, 216]. When added to this underlying predisposition, coding 
sequence mutations such as occur in Akita proinsulin trigger a cascade of misfolding, 
blockade of ER export, intracellular accumulation of the mutant proinsulin, and a defect in 
the production and secretion of co-expressed wild-type insulin [217, 218]. Although it was 
initially thought that misfolded proinsulin (as occurs in Akita mice) cannot promote 
formation of aberrant intermolecular disulfide bonds [219], this conclusion was inconsistent 
with the demonstration of an increase in disulfide-bonded proinsulin aggregates in Akita 
islets [14]. It is now thought that aberrant intermolecular disulfide-bonded proinsulin is not 
only a notable feature in Akita mouse islets, but also occurs in WT mouse islets [219], 
underscoring that WT proinsulin already has a propensity to misfold within the ER of 
pancreatic beta cells [93, 165, 220].
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5.1 | HETEROZYGOUS PROINSULIN MUTATIONS ARE A (RARE BUT SEVERE) CAUSE OF 
PROINSULIN MISFOLDING
Proinsulin misfolding underlies the syndrome known as Mutant INS gene-induced Diabetes 
of Youth (MIDY) [32, 221], a human version of the disease seen in Akita mice. Clinically, 
the majority of patients with this syndrome develop life-long insulin-deficient diabetes 
mellitus that typically begins in the neonatal period (although – depending upon the 
mutation – may occasionally be initiated later in life [25]). As expected in neonatal diabetes, 
it is not uncommon to observe very rapid clinical development of pancreatic beta cell failure 
[222]. Although patients with MIDY do not have insulin autoantibodies [223, 224], the 
disease has often been labeled clinically as type 1 diabetes [225]. Notably, all MIDY patients 
are heterozygotes, indicating the presence of co-expressed WT proinsulin. Recently, the first 
large animal (porcine) model of the proinsulin-C(A7)Y mutation has been developed [226, 
227] which recapitulates all of the features of MIDY as elucidated both in Akita mice and 
humans [25, 216]. It is known that the detrimental effects of MIDY mutant proinsulin 
expression is dose-dependent and related to the mutant : WT ratio [218, 226, 228–230]. In 
Akita mice, the mutant proinsulin protein represents 36% of total newly-synthesized 
proinsulin translation product [231]; in transgenic MIDY pigs, total INS mRNA is ~44% 
mutant and ~56% WT; and in humans with MIDY the mutant : WT ratio is believed to be 
50% : 50%. The transgenic MIDY pigs first develop fasting hyperglycemia in the diabetic 
range between 2–3 months of life, and at 4.5 months of life when fasting glucose is > 300 
mg/dL, fasting circulating insulin and C-peptide levels are low, corresponding with 
decreased pancreatic insulin, decreased beta cell mass, and a markedly expanded and 
fragmented beta cell ER [226, 227]. From there, the animals progress to develop ketosis as 
detected by a further decrease of insulin immunostaining and a drastic loss of conventional 
islet structures (see Figure 9), similar to what is reported in Akita mice [232].
In addition to aberrant intramolecular proinsulin folding, the mutant proinsulin-C(A7)Y 
forms aberrant disulfide-linked protein complexes [231] that include (and co-precipitate) 
WT bystander proinsulin [230] in the ER [233], thereby blocking WT proinsulin 
intracellular transport through the secretory pathway and causing beta cell ER stress [231] 
while also impairing downstream insulin production and insulin secretion [231], leading to 
diabetes [232]. Other MIDY mutants generate much the same pathological phenotype [32, 
234] although the intracacies of intramolecular disulfide mispairing differ for individual 
MIDY mutants [165].
5.2 | LIPOTOXICITY AND PROINSULIN MISFOLDING
Free fatty acids have pleiotropic effects on pancreatic beta cells. In the near term, fatty acids 
such as palmitate can augment insulin synthesis and secretion [235]. However, chronic fatty 
acid exposure significantly damages beta cells, and together, high glucose and fatty acid 
exposure can synergize (negatively) to trigger beta cell ER stress [236]. Clinically, increased 
levels of saturated free fatty acids, especially palmitate, tend to predict an increased risk of 
type 2 diabetes [237].
Palmitate feeding to beta cells has been found to acutely increase cytosolic calcium and 
decrease ER calcium, leading to rapid phosphorylation of PERK, as well as other indicators 
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of ER stress [238]. In a pancreatic beta cell line fed palmitate for 6 h, proinsulin 
(fluorescently-tagged) was found to shift its intracellular distribution to become accumulated 
within the ER, with evidence of expansion of the ER compartment [239]. Although it 
remains to be examined directly, these findings are highly suggestive of the possibility of 
fatty acid (palmitate) exposure leading to proinsulin misfolding.
One recent study has suggested that the beta cell ER stress generated by fatty acids might 
also be mediated through ER calcium depletion via calcium leak (to the cytosol) through the 
ER translocon [240]. Interestingly, the protein synthesis elongation inhibitor anisomycin has 
been found to be beta cell-protective and prevents loss of ER calcium upon palmitate 
treatment, presumably by keeping the Sec61 translocation channel occupied with ribosomes. 
While anisomycin also enhances IRS-2 phosphoryation, making it is difficult to exclude 
other indirect effects, it is worth noting that using a protein synthesis inhibitor to simply 
decrease the rate of proinsulin synthesis should help to improve proinsulin folding 
efficiency. As a proof of concept, decreased insulin gene expression has similarly been 
shown to significantly alleviate ER stress and enhance Akt phosphorylation (and even 
promote beta cell proliferation) – and these effects that accompany decreased proinsulin 
synthesis can be observed independently from the use of any general protein synthesis 
inhibitor or other drugs [241].
Recent studies in db/db mice have suggested that suppression of Elovl6 (a microsomal 
enzyme that converts saturated and mono-unsaturated C-16 fatty acids to C-18 species) can 
enhance islet insulin content leading to improved insulin secretion and glycemic control 
[242]. This is clearly an interesting new system in which to explore potential lipotoxic 
effects on proinsulin biosynthesis and folding. Further, several compounds have been 
identified that not only enhance survival of primary human beta cells (as well as rodent beta 
cell lines) treated with tunicamycin (that inhibits N-linked protein glycosylation in the ER 
with consequent ER stress) and palmitate, but also enhance glucose-stimulated insulin 
secretion in these stressed cells [243]. These and other candidate compounds need further 
examination for their potential ability to decrease proinsulin misfolding, in addition to their 
salutary effects on ER stress and ER stress-mediated cell death.
5.3 | CYTOKINES AND PROINSULIN MISFOLDING
Free fatty acids may also promote inflammation in islets, potentially via TLR4 activation 
and macrophage stimulation resulting in the local release of inflammatory cytokines 
including interleukin-1β (IL-1β) [244], as well as by other potential mechanisms [245]. The 
signaling from IL-1β, and interferon-γ (IFN-γ) and IFN-α, have been suggested to perturb 
the ER microenvironment [246], especially by lowering free calcium in the ER lumen [247] 
(perhaps by inhibitory effects on luminally-directed SERCA-2 or other ER calcium pumps 
[248–250]). As described in preceding sections, the proinsulin folding process in the ER 
depends significantly on the ER microenvironment to facilitate both entry of newly-
synthesized (pre)proinsulin into the ER as well as the activity of folding chaperones and 
oxidoreductases that operate within a regulated redox range and a controlled level of ER 
luminal calcium [156]. Protection from cytokine-mediated toxicity has been reported in beta 
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cells bearing ectopically-expressed mitochondrial catalase to selectively limit mitochondrial 
ROS production [251].
Nitric oxide generation in or around islets has also been suggested to be linked to cytokine 
response with lowered beta cell ER luminal calcium, leading to beta cell apoptosis [252], but 
the significance of these observations — at least in human beta cells — is still not very clear 
[253]. Cytokine-mediated lowering of ER luminal calcium levels is indeed thought to be 
linked to ER stress, but while the underlying mechanism of calcium lowering and the 
applicability of the findings for human islets are ongoing areas investigation [249], a recent 
study suggests that inadequate upregulation of Spry2 (which is downstream of the ER stress-
mediated PERK pathway) could limit SERCA-2 activity and also lead to diminished INS 
mRNA expression [254].
Human beta cells cultured short-term with IL-1β and IFN-γ have been found to exhibit 
unabated proinsulin synthesis (with perturbed proinsulin-to-insulin conversion leading to 
increased unprocessed proinsulin secretion [255]). Remarkably, however, after 48 h of 
inflammatory cytokine exposure, there is a dramatic loss of islet insulin content and 
diminished glucose-stimulated insulin secretion [253]. Proinsulin misfolding under these 
conditions is a topic that clearly needs further investigation, but others have already gone 
ahead to employ an IL-1β receptor antagonist (as a potential therapy for type 2 diabetes) 
with a beneficially increased ratio of insulin : proinsulin in the circulation [256].
Interestingly, if cytokines do alter the ER microenvironment in a manner that triggers 
chronic, severe proinsulin misfolding leading to hyperactivation of the IRE1α limb of the 
ER stress response, this apparently can trigger a signaling cascade that can lead ultimately to 
still more IL-1β secretion from pancreatic beta cells [257]. If so, it is conceivable that 
inflammatory cytokine exposure could trigger a dangerous positive feedback loop in which 
perturbation of the beta cell ER could ultimately result in the progressive generation of more 
inflammatory cytokines, worsening beta cell function and survival. An additional 
consequence of inflammatory cytokine stimulation may include ER stress-mediated 
formation and release of proinsulin-containing exosomes that could stimulate antigen-
presenting cells, leading to beta cell autoimmunity [258].
5.4 | AGING AND PROINSULIN MISFOLDING
Aging cells are thought to accumulate misfolded proteins through a functional decline in the 
machinery necessary for maintenance of protein homeostasis [259]. Glucose intolerance and 
Type 2 diabetes incidence also tend to increase with age and this can be attributed primarily 
to an age-related decline in insulin secretion [260–264]. The detrimental effects of aging do 
not appear as evident in mouse models [265]. Nevertheless, isolated islets from NOD mice 
(a model of autoimmunity) display age-dependent increases in parameters of ER stress and 
morphologic alterations in ER structure by electron microscopy [266] (as well as an increase 
in islet levels of cytosolic hsp90 [267]), which accompany a progressive defect in insulin 
secretion [268]. While it is unclear that such age-dependent predispositions also exist in 
wildtype mice, the immunohistochemical detection of insulin in the islets of wildtype 
Sprague-Dawley rats has been noted to decline significantly with age [269]. Direct 
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evaluation of proinsulin misfolding as a function of age remains a fertile area for further 
investigation.
5.5 | HYPERGLYCEMIA AND PROINSULIN MISFOLDING
From meal-to-fasting-to-meal, new insulin synthesis is dramatically increased or decreased 
by changes in prevailing blood glucose levels [270], primarily through up- and down-
regulation of preproinsulin mRNA translation (along with that of proinsulin processing 
enzymes [271], although this coordinate expression may not persist in type 1 diabetic human 
pancreata that generate proinsulin but no detectable insulin or C-peptide [272].) Ordinarily, 
the translational control of proinsulin biosynthesis is designed to replete the beta cell 
secretory granule pool size; however, there are many pathophysiological examples of a 
discord between a high magnitude of proinsulin biosynthesis that is not matched by a similar 
steady-state number of stored insulin secretory granules [273, 274]. Such may be the case in 
type 2 diabetes. Although it has been reported that only a few percent of pancreatic insulin 
may be released for each meal, granule release iterated over time may deplete the storage 
pool, as reported in leptin receptor-deficient db/db diabetic mice [274] in which 
hyperglycemia has been reported as the predominant factor underlying the defective beta cell 
phenotype [275]. In such mice, proinsulin biosynthesis is markedly increased, the proportion 
of intracellular proinsulin is also increased, and the fraction of beta cell area occupied by ER 
is doubled [274]. Under these conditions, the quantity of misfolded proinsulin is expected to 
be increased. Proinsulin synthesis in WT pancreatic islets increases shortly after exposure of 
islets to high glucose levels, and with that biosynthetic increase is observed an increase in 
nonnative intramolecular disulfide isomers (see Figure 10, left two lanes).
Additional stimulation of proinsulin synthesis is observed in islets in which PERK is absent 
or inactive — exposure of such islets to elevated ambient glucose levels increases proinsulin 
biosynthesis still further, making nonnative intramolecular disulfide isomers still more 
abundant (Figure 10, right two lanes; and similar observations of proinsulin misfolding have 
been made in islet beta cells bearing eIF2alpha mutation that prevents its phosphorylation by 
PERK [146]). It is thus of particular interest that db/db diabetic mice also show little 
evidence of PERK being active even in the face of ongoing high level proinsulin synthesis 
[274]. And despite this active proinsulin biosynthesis, these are not conditions in which 
intracellular insulin levels are maintained – in fact there is dramatic beta cell insulin 
depletion, indicating significant functional defects along the pathway of proinsulin folding, 
trafficking, processing, and storage [276].
Indeed, in WT mice trying to dispose of high glucose (continuous intravenous infusion of 
277 µmoles/h) over a 4-day period, blood glucose is observed to rise within the normal range 
by 5–10 mg/dL each day, while circulating insulin in the bloodstream begins to decline 
between days 2, 3, and 4 [277]. As extracellular glucose levels rise higher still, beta cells can 
continuously sustain a very high level of proinsulin biosynthesis [278]. Only at the highest 
extracellular glucose levels consistent with full-blown diabetes (e.g., >500 mg/dL) do beta 
cells (at least rodent beta cells) finally show a tendency to decrease insulin mRNA 
accompanied by diminished proinsulin translation [279] as well as the formation of 
ubiquitylated intracellular protein aggregates [280]. While it is uncertain what proteins may 
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accumulate in these aggregates, it is certain that newly-synthesized proinsulin itself, when 
translated under high glucose conditions, forms protein complexes [220]. Thus all evidence 
points to the notion that sustained hyperglycemia is a major pathological trigger for 
proinsulin misfolding.
6 | FUTURE PERSPECTIVES
Even as we uncover more details about the earliest events of preproinsulin biosynthesis and 
folding, many questions remain. Regarding our considerations of the post-translational 
translocation process, more information is needed about the cytosolic chaperones that 
prevent untranslocated preproinsulin aggregation in order to maintain its post-translational 
translocation-competence. We also hope to learn how cytosolic preproinsulin is guided to the 
ER membrane. Further, more information is needed to identify all the components at the ER 
membrane that first engage nascent cytosolic preproinsulin and presents the signal peptide n-
region positive charge to the Sec61 translocon. Perhaps the most important work still needed 
on preproinsulin translocation is to uncover the pathophysiologic implications of the 
different translocation mechanisms. Specifically, it has been suggested that ER translocation 
efficiency may be regulated under physiological conditions, and dysregulated under 
pathological conditions. It is possible that under ER stress, translocation efficiency may 
decrease, potentially re-routing some secretory (and membrane) proteins for cytosolic 
degradation — a process termed “pre-emptive quality control” [281–283]. Although pre-
emptive quality control might reduce protein load into the ER, it might also result in 
proteotoxicity if these proteins are not efficiently cleared from the cytosol [281].
The above considerations culminate in a key question: how long is an untranslocated 
preproinsulin molecule allowed to spend in the cytosol before it is deemed unable to 
complete translocation and is targeted for degradation, and what mechanism initiates the 
switch from translocation to degradation? Once this is known, it should be possible to test 
the question of whether ER stress causes accumulation of undegraded preproinsulin 
molecules and/or contributes to beta cell failure in type 1 or type 2 diabetes [160, 216, 266, 
284, 285]?
Regarding our considerations of the proinsulin folding pathways, we are impressed by the 
remarkable experiments of nature, defined as MIDY mutations, to highlight structural 
determinants of foldability. Together, biochemical, biophysical and cell biological studies 
suggest that sequence variation in insulin is enjoined by the intersection of multiple inter-
dependent constraints (Figure 11). Yet salient overall questions remain, particularly with 
respect to the mechanism of native disulfide pairing. The structural differences between the 
native fold and competing meta-folds containing non-native disulfide bridges can be subtle. 
For example, mini-proinsulin (which contains a peptide bond between residues B29 and A1) 
refolds in vitro more efficiently than proinsulin [286] and yet in S. cerevisciae forms 
predominantly a metastable disulfide isomer that passes ER quality control and is secreted. 
These data suggest that the ER folding machinery of a eukaryotic cell can selectively target 
folding into a non-ground-state conformation; i.e., global thermodynamic stability is not the 
critical parameter, which can thus lead to states of “stealth” misfolding, including the 
secretion of a protein caught in a kinetic folding trap. One future perspective is the 
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development of refined assays to reveal such stealth proinsulin misfolding in pancreatic beta 
cells.
In considering the ER folding environment for proinsulin, there are many unanswered 
important interesting questions that require further study. In particular, why do generalized 
perturbations of ER proteostasis — in both human cases and murine genetic models [140, 
141] — especially disrupt beta cell function and survival? One plausible explanation may be 
that as opposed to other cell types, glucose also stimulates proinsulin mRNA translation via 
activation of PP1 phosphatase to dephosphorylate eIF2α [287]. As a result, increased 
accumulation of proinsulin in the ER may activate the UPR to a level that may promote beta 
cell dysfunction. Specifically, post-prandial glucose excursions promote metabolic activity 
in beta cells that may generate ROS that accompanies ER stress [288]. Beta cells are 
particularly sensitive to ROS as they express low levels of antioxidant enzymes, such as 
catalase, glutathione peroxidase, and superoxide dismutase [289], which may explain why 
antioxidants can limit beta cell failure in several mouse models [147, 148, 156].
Another interesting unanswered feature of disorders of ER stress response is the apparent 
link between type 2 diabetes and neurodegeneration, such as is seen animals with loss of 
function mutations in the ER chaperone DNAJc3/p58IPK. Intriguingly, many nucleotide 
polymorphisms in genes identified for neurodegenerative diseases, such as the involvement 
of PERK in progressive supranuclear palsy (PSP) [290] and in Alzheimer’s disease, may 
also impact beta cell function. These observations suggest a common sensitivity to ER 
dysfunction in both neurons and beta cells. Alternatively, could insulin signaling contribute 
to neurodegeneration? In the coming years, tissue-specific and temporally-controlled genetic 
models should help to enlighten this field.
Regarding our consideration of proinsulin misfolding under diabetogenic conditions, there 
also remains much to learn. There is strong reason to believe that the time during which 
proinsulin is most susceptible to misfolding is immediately upon translocation, prior to the 
completion of chaperone- and oxidoreductase-assisted folding. During this period, wild-type 
proinsulin in healthy beta cells is known to form disulfide-linked proinsulin complexes 
[291]. Ultimately it will be important to develop assays that can establish whether such 
complexes that persist for more than a few minutes after synthesis are true folding 
intermediates from which native proinsulin is still recoverable — or do they represent folded 
states that are irremediably “off pathway”?
Finally, additional critical studies are still needed to directly examine nonmutant proinsulin 
folding status in “garden variety” type 2 diabetes, both in rodent models and in humans. 
Based on the foregoing considerations in this review, we present an hypothesis in Figure 12. 
We suggest that misfolded proinsulin beyond a critical threshold level impairs the ER export 
of bystander proinsulin molecules, similar to what occurs in MIDY. A decrease of proinsulin 
ER export, or absolute proinsulin levels (through ERAD and autophagy) limits proinsulin 
available for insulin production. The ensuing insulin deficiency leads to hyperglycemia 
which itself — along with other potential factors, promote further proinsulin misfolding, 
resulting in an unfortunate positive feedback loop (Figure 12). We hypothesize that the 
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accumulation of misfolded proinsulin contributes to beta cell ER stress, and in conjuction 
with the glucolipotoxicity of diabetes, contributes to pancreatic beta cell death.
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Figure 1. Human preproinsulin and its signal peptide mutations associated with diabetes in 
humans.
Preproinsulin is comprised of the signal peptide (light blue), insulin-B chain (red), C-peptide 
(white), and insulin-A chain (green). Signal peptide mutations reported to cause diabetes in 
humans are indicated. RM: recessive mutation; T2D: type 2 diabetes; MODY: maturity onset 
diabetes of the young; NDM: neonatal diabetes; MIDY: mutant INS-gene induced diabetes 
of youth.
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Figure 2. Preproinsulin translocation across the ER membrane.
Newly synthesized preproinsulin molecules can be translocated into the ER through both 
SRP-dependent co-translational translocation and SRP independent post-translational 
translocation. In co-translational translocation, SRP recognizes and binds the preproinsulin 
SP emerging from the ribosomes, forming SRP-ribosome-preproinsulin complexes that 
interact with SRP receptor on the ER membrane, thereby targeting the nascent preproinsulin 
to the Sec61 translocon. For post-translational translocation, although Sec62 is reportedly 
involved, the chaperones maintaining translocation competence of fully-synthesized 
preproinsulin in the cytosol, and its mechanism of delivery to the ER membrane, have not 
yet been identified. This figure is reprinted with modification, with permission from 
Vitamins and Hormones (reference 19).
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Figure 3. The n-region positive charge in preproinsulin signal peptide is critical for efficient post-
translational translocated of preproinsulin.
A. 293T cells transfected with plasmids encoding preproinsulin wild-type (WT) or R6C 
mutant were pulse-labeled with 35S-Met/Cys for 5 min followed by 0, 10, or 30 min of chase 
in the presence of 10 µM MG132 and 10 µg/ml cycloheximide (CHX). Post-translational 
translocation of preproinsulin-WT and R6C were analyzed by immunoprecipitation, SDS-
PAGE, and phosphorimaging. B. The signal-uncleaved and signal-cleaved forms of 
preproinsulin were quantified; the signal-uncleaved fraction is shown. Reprinted with 
permission from the J. Biol. Chem. (reference 26).
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Figure 4. Energy landscape paradigm.
(A) Successive disulfide pairing enables a sequence of folding trajectories on ever-steeper 
funnel-shaped free-energy landscapes. (B) Preferred pathway of disulfide pairing. Initial 
formation of cystine A20-B19 (left) is directed by a nascent hydrophobic core comprising 
the central B-domain alpha-helix (residues B9-B19), part of the C-terminal B-chain beta-
strand (B24-B26), and part of the C-terminal A-domain alpha-helix (A16-A20). Alternative 
pathways mediate successive disulfide pairing (middle panel) leading in turn to the native 
state (right). The mechanism of disulfide pairing is perturbed by clinical mutations 
associated with a monogenic syndrome of DM due to toxic misfolding of the variant 
proinsulin in the ER. Figure is adapted from Ref [66]; panel A is adapted from an image 
kindly provided by J. Williamson.
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Figure 5. Critical sites governing the foldability of proinsulin are widely distributed in insulin.
Asterisk indicates N-terminal segment of the B chain, which promotes foldability but is 
dispensable in the mature hormone [98]. Conserved side chains in or adjoining the C-
terminal -helix of the A chain (LeuA16 and TyrA19; Ca purple spheres) and at multiple sites 
in the B chain (Ca red spheres) impair insulin chain combination in accord with studies of 
mutant proinsulins in mammalian cell lines and the distribution of clinical non-cysteine 
mutations in the insulin gene. Contacts between the side chains PheB1 and IleA13 (Ca blue 
spheres), although not well ordered in the native state, contribute to the cellular foldability of 
proinsulin. Residues IleA2, TyrB26, and ProB28 (Ca green spheres) contribute to the structure 
and stability of the native state but are not required for efficient disulfide pairing in chain 
combination. Disulfide bridges are as indicated (orange). Coordinates were obtained from 
Protein Databank file 4INS and correspond to molecule 1 of the classical 2-Zn insulin 
hexamer [99].
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Figure 6A. Structure and assembly of insulin with key roles of PheB24.
Assembly of zinc insulin hexamer. The monomeric hormone (A- and B chains, top panel) 
forms zinc-free dimers via anti-parallel association of B-chain α-helices and C-terminal β-
strands (brown, middle panel); two zinc ions then mediate assembly of three dimers to form 
classical hexamer (T6, bottom panel). The A chain is shown in yellow (ribbon), and the B 
chain in light brown (B1-B19) or brown (B20-B30). Conserved aromatic residues PheB25 
and TyrB26 are shown as black sticks whereas PheB24 is red. The Zn2+ ion is depicted in 
blue. The figure was in part modified from reference [109] with permission of the authors. 
Coordinates were obtained from 4INS. Figure 6B and6C. Structure of IR receptor 
ectodomain. (B) Λ-shaped IR ectodomain homodimer. One protomer is shown as a ribbon 
(labeled), and the other as molecular surface. Domains are: L1, first leucine-rich repeat 
domain; CR, cysteine-rich domain; L2, second leucine-rich repeat domain; FnIII-1–3, 
respective first, second and third fibronectin Type III domains; and αCT, α-chain C-terminal 
segment. (C) Model illustrating insulin in its classical free conformation bound to Site 1 of 
the microreceptor (L1-CR + αCT 704–719; designated IR) [104, 105]. L1 and part of CR 
are shown in cyan, and αCT in magenta. PheB24, PheB25 and TyrB26 are as in Figure 6A. 
The B chain is shown in dark gray (B6-B19); the position of the brown tube (residues B20-
B30) would lead to steric clash between B26-B30 and αCT. The figure was in part modified 
from references [109] and [110] with permission of the authors. Coordinates were obtained 
from PDB entries 4OGA, 2DTG, and 3W11.
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Figure 7. Illustration of ER stress response pathways and their activation by excessive proinsulin 
synthesis.
Increased synthesis and abundance of newly-made proinsulin correlates with increased BiP 
binding to proinsulin, which is associated with dimerization and activation of PERK and 
IRE1α proteins, and translocation of full-length ATF6α to the Golgi complex for proteolytic 
processing. Subsequent translation of ATF4 and spliced XBP1, together with the liberated 
cytosolic domain of ATF6α, activate major transcriptional limbs of the stress response 
designed to restore proteostasis in the ER.
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Figure 8. Proinsulin undergoes oxidative folding upon biosynthetic delivery into the ER lumen.
Upon arrival in the ER lumen, proinsulin undergoes oxidative folding to form its three 
essential disulfide bonds, which is thought to be facilitated by members of the PDI family of 
ER oxidoreductases. The Ero1 family of upstream oxidases are considered important in 
shuttling the reducing equivalents (originating from proinsulin substrate) to molecular 
oxygen, while regenerating oxidized PDI proteins. In addition, Ca2+ dependent and –
independent chaperones such as BiP and p58IPK also play indispensable roles in assisting 
proinsulin folding, along with key ER resident proteins for other secretory protein substrates, 
such as calreticulin and calnexin.
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Figure 9: Pancreata and beta cells of transgenic MIDY pigs, reproduced from [226, 227].
(A) WT pig pancreas stained by immunoperoxidase with anti-insulin, counterstained with 
DAPI. (B) Two-year old transgenic MIDY pig pancreas stained as in panel A. (C) 
Transmission electron microscopy of pancreas from a 4.5-month old transgenic MIDY pig 
bearing only few beta cell secretory granules (arrows) and hypertrophied ER (asterisks).
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Figure 10: Two distinct nonnative intramolecular disulfide isomers of proinsulin (at arrows; the 
native isomer position is also indicated).
Isolated mouse pancreatic islets were preincubated for 40 min at the respective glucose 
concentrations, and were then pulse-labeled with 35S-amino acids at these glucose 
concentrations. The islets were lysed, immunoprecipitated with anti-insulin, and analyzed by 
nonreducing Tris-tricine-urea-SDS-PAGE as in [93]. An asterisk identifies a proinsulin 
conversion intermediate, the processing of which takes place beyond the ER.
Liu et al. Page 47
Diabetes Obes Metab. Author manuscript; available in PMC 2019 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 11. Evolution of insulin is constrained by multiple factors.
Venn diagram illustrating influence of protein misfolding, foldability and assembly as well 
as the traditional importance of direct biological function at the receptor level.
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Figure 12: An hypothesis linking proinsulin misfolding to the pathogenesis of type 2 diabetes.
Proinsulin must fold to become exported from the endoplasmic reticulum (ER) and make 
insulin (pathway in blue). Many factors may cause proinsulin misfolding (see text). 
Misfolded proinsulin molecules (in red) recruit bystander proinsulin molecules into 
complexes defective for ER export. Decreased export of proinsulin decreases insulin 
production and secretion leading to higher blood glucose. Hyperglycemia is a factor 
promoting additional biosynthesis of misfolded proinsulin creating a dangerous positive 
feedback loop that promotes diabetes. Ultimately, high level proinsulin misfolding can 
trigger ER stress and beta cell death.
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